Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Jazz Pharma Plc
(NQ:
JAZZ
)
108.39
-0.25 (-0.23%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Sep 5, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Jazz Pharma Plc
< Previous
1
2
...
6
7
8
9
10
11
12
13
Next >
Aurinia Pharmaceuticals Skids With Its Buyout Thesis Hanging By A Thread
July 15, 2022
The company just hired three new executives, likely putting a buyout in the rearview.
Via
Investor's Business Daily
Cannabis Stocks Struggle Through Q2 2022
July 15, 2022
An overview of how cannabis stocks fared in Q2 and what investors should understand about the space.
Via
Talk Markets
Needham Previews Neurocrine's Upcoming Mid-Stage Data from Essential Tremor Study
July 11, 2022
Needham previews the upcoming Phase 2 data readout for Neurocrine Biosciences Inc's (NASDAQ: NBIX) NBI-827104, a t-type calcium channel blocker in essential tremor (ET), by mid-2022.
Via
Benzinga
Brazilian Fund Invests $19M In US Cannabis Stocks
July 05, 2022
As scientific research continues to produce studies on the health benefits of cannabis and CBD and legalization of the plant grows across the globe, not unsurprisingly traditional investment firms are...
Via
Benzinga
What SVB Says On Axsome's Strategy Review On Sunosi For Sleeping Disorder
June 29, 2022
Axsome Therapeutics Inc (NASDAQ: AXSM) held an investor event to review its strategy with Sunosi, which is indicated for excessive daytime sleepiness (EDS) in narcolepsy and obstructive sleep apnea...
Via
Benzinga
Jazz Pharma, Sumitomo Pharma Ink Licensing Pact For Sleeping Disorder Candidate
May 05, 2022
Via
Benzinga
Jazz Pharmaceuticals' Late-Stage Multiple Sclerosis Study Misses Primary Endpoint
June 28, 2022
Jazz Pharmaceuticals (NASDAQ: JAZZ) announced top-line results from the Phase 3 clinical trial investigating nabiximols oromucosal spray (JZP378) on clinical measures of spasticity in individuals with...
Via
Benzinga
Jazz Pharma's Cannabidiol Mixture Spray Misses Primary Goal In Multiple Sclerosis Spasticity
June 28, 2022
Via
Benzinga
Switzerland Removes Medical Marijuana Access Limitations As Demand Rises
June 23, 2022
The Swiss government confirmed that it will remove limitations on medical marijuana use, starting August 1st, 2022.
Via
Benzinga
This Pharmaceutical Company Is Moving Beyond CBD
June 23, 2022
The applications for cannabidiol (CBD) and cannabinoid-based therapeutics are many. Many novel treatments have been, and are continuing to be, discovered using these compounds. The industry is huge...
Via
Benzinga
Leisuretown: Diplo And Rob Dyrdek's New Cannabis Seltzers Launch In California Via Agreement With HERBL
June 23, 2022
Thomas Wesley Pentz, better known for his artistic name, Diplo, partnered with California cannabis beverage company Leisuretown, professional skateboarder Rob Dyrdek and cannabis supply chain company...
Via
Benzinga
4 Analysts Have This to Say About Jazz Pharmaceuticals
June 14, 2022
Jazz Pharmaceuticals (NASDAQ:JAZZ) has observed the following analyst ratings within the last quarter:
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For June 14, 2022
June 14, 2022
Upgrades
Via
Benzinga
Euro Food Agency Concerned About Health Effects Of CBD, Asks For More Research
June 10, 2022
The European Food Safety Authority (EFSA) is asking for more research on the effects of CBD on humans.
Via
Benzinga
North Carolina House Says Yes To Bill Allowing FDA-Approved THC Drugs, Will This Kill Full Medical Marijuana Legalization?
June 09, 2022
The North Carolina House passed Senate Bill 448, legalizing FDA-approved THC medications in a 92-9 vote, reported The Carolina Journal.
Via
Benzinga
The Daily Biotech Pulse: Veru Seeks Emergency Use Nod For COVID-19 Therapy, Vincerx Cuts Workforce, Moderna Starts Dosing In Flu Vaccine Study
June 07, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours:
Via
Benzinga
FDA Battles Over CBD Hype Yet Again, This Time Warns Businesses Selling Illegal CBD For Food-Producing Animals
May 27, 2022
The Food and Drug Administration (FDA) sent letters to four CBD companies warning them against selling unauthorized CBD products for use in food-producing animals. Companies being warned are Haniel...
Via
Benzinga
Global Central Nervous System Treatment Market Is Expected to Reach $166 Billion In 2028
May 26, 2022
Palm Beach, FL – May 26, 2022 – FinancialNewsMedia.com News Commentary – Worldwide, there is a rapid increase in the prevalence and incidence of neurological disorders such as multiple sclerosis,...
Via
FinancialNewsMedia
Exposures
COVID-19
Jazz Pharmaceuticals Stock Sees Rising Price Performance With Jump To 81 RS Rating
May 17, 2022
Jazz Pharmaceuticals sees its Relative Strength Rating move into the 80-plus level.
Via
Investor's Business Daily
Jazz Pharmaceuticals's Return On Capital Employed Insights
May 17, 2022
Pulled from Benzinga Pro data, Jazz Pharmaceuticals (NASDAQ:JAZZ) posted Q1 earnings of $1.65 million, an increase from Q4 of 104.66%. Sales dropped to $813.72 million, a 9.26% decrease between...
Via
Benzinga
What Does HC Wainwright Have To Say On Avadel's Narcolepsy Candidate's Potential Approval?
May 11, 2022
Avadel Pharmaceuticals PLC (NASDAQ: AVDL) reported 1Q results and provided updated color on the U.S. marketing application for FT218.
Via
Benzinga
Jazz Pharmaceuticals Completes U.S. Divestiture Of Sunosi To Axsome Therapeutics, What's Next?
May 09, 2022
Jazz Pharmaceuticals plc (NASDAQ: JAZZ) has completed the divestiture of Sunosi (solriamfetol) in the U.S.
Via
Benzinga
What 6 Analyst Ratings Have To Say About Jazz Pharmaceuticals
May 05, 2022
Jazz Pharmaceuticals (NASDAQ:JAZZ) has observed the following analyst ratings within the last quarter:
Via
Benzinga
The Daily Biotech Pulse: AstraZeneca's 3 Product Updates, Jazz Pharma Licenses Sleeping Disorder Product, Argenx Aces Bleeding Disorder Study
May 05, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours:
Via
Benzinga
Jazz Pharma Reports Q1 Epidiolex Sales Increased 6% To $157.9M YoY
May 05, 2022
Jazz Pharmaceuticals plc (NASDAQ: JAZZ) released financial results for the first quarter of 2022.
Via
Benzinga
Jazz Pharmaceuticals: Q1 Earnings Insights
May 04, 2022
Jazz Pharmaceuticals (NASDAQ:JAZZ) reported its Q1 earnings results on Wednesday, May 4, 2022 at 05:05 PM. Here's what investors need to know about the announcement.
Via
Benzinga
The Daily Biotech Pulse: Kezar Life's Lead Asset Fails, Brickell Biotech Offloads Late-Stage Asset, Connect Biopharma Ulcerative Colitis Trial Disappoints
May 04, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours.
Via
Benzinga
EXCLUSIVE: Aurora Cannabis CEO 'Absolutely Confident' Company Will Be EBITDA-Positive By Year's End
April 20, 2022
Miguel Martin, CEO of Aurora Cannabis Inc (NASDAQ: ACB), discussed growing Aurora into the leader of the international medical cannabis market at the Benzinga Cannabis Capital Conference on Wednesday.
Via
Benzinga
Axsome Therapeutics Stock Rockets As Its First FDA Approval Looks Imminent
April 19, 2022
The company agreed to the FDA's post-marketing requirements for a depression drug.
Via
Investor's Business Daily
Avicanna's Cannabinoid Drugs To Reach Brazil Via Its First 'Big Pharma' Deal
April 13, 2022
Via
Benzinga
< Previous
1
2
...
6
7
8
9
10
11
12
13
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.